U.S. stocks closed another record-setting week with a muted performance. The S&P 500 edged down by 0.1% Friday from its ...
Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
The Dow Jones Industrial Average edged up to another record high while declines in tech stocks pulled other indexes lower.
Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...